2017 | 2016 | 2015 | 2014

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress

10/26/17

SAN DIEGO--(BUSINESS WIRE)--Oct. 26, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018

09/25/17

-- Decision follows successful Scientific Advice meeting with European Medicines Agency -- SAN DIEGO--(BUSINESS WIRE)--Sep. 25, 2017-- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) toda

Read More

Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State

09/20/17

Analysis to Be Presented in Oral Session at the 30th Annual Congress of The European Society of Intensive Care Medicine SAN DIEGO--(BUSINESS WIRE)--Sep. 20, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Co

Read More

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501

08/28/17

– Priority Review Granted – SAN DIEGO--(BUSINESS WIRE)--Aug. 28, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) h

Read More

La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501

08/08/17

SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), today announced that the Company has initiated an expanded access program (EAP) in the United States to p

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress

07/27/17

SAN DIEGO--(BUSINESS WIRE)--Jul. 27, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

05/21/17

SAN DIEGO--(BUSINESS WIRE)--May 21, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress

04/27/17

SAN DIEGO--(BUSINESS WIRE)--Apr. 27, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

03/23/17

SAN DIEGO--(BUSINESS WIRE)--Mar. 23, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients

Read More

La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock

03/20/17

SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company), a leader in the development of innovative therapies intended to significantly improve outcomes in patients s

Read More

La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501

02/27/17

-- Primary efficacy endpoint analysis highly statistically significant (p<0.00001) -- Trend toward longer survival observed -- New Drug Application planned for second half of 2017 -- Company to h

Read More

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress

02/23/17

SAN DIEGO--(BUSINESS WIRE)--Feb. 23, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts